04937nam 22008295 450 991043801490332120200701072150.01-907673-94-610.1007/978-1-907673-94-8(CKB)3710000000119077(EBL)1782082(SSID)ssj0001243251(PQKBManifestationID)11838309(PQKBTitleCode)TC0001243251(PQKBWorkID)11268760(PQKB)10635325(DE-He213)978-1-907673-94-8(MiAaPQ)EBC1782082(PPN)178779695(EXLCZ)99371000000011907720140528d2013 u| 0engur|n|---|||||txtccrHandbook of HER2-targeted agents in breast cancer[electronic resource] /by Ricardo H Alvarez, Javier Cortés, Leticia Mattos-Arruda, Mary Falzon, Angelica Fasolo, Michael Gandy, Luca Gianni, Nadia Harbeck, Martine Piccart, Stefania Zambelli, Dimitrios Zardavas1st ed. 2013.Tarporley :Springer Healthcare Ltd. :Imprint: Springer Healthcare,2013.1 online resource (107 p.)Description based upon print version of record.1-322-13345-X 1-907673-93-8 Includes bibliographical references.Introduction and background biology -- HER2 testing -- HER2-positive breast cancer: adjuvant and neoadjuvant therapy -- HER2-positive metastatic breast cancer: first-line treatment -- HER2-positive metastatic breast cancer: second-line treatment -- Emerging targeted agents for HER2-positive breast cancer.Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year.  Of these cases, approximately  15–25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes.  However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer  provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.Oncology  Primary care (Medicine)General practice (Medicine)Internal medicinePharmacotherapyOncologyhttps://scigraph.springernature.com/ontologies/product-market-codes/H33160Primary Care Medicinehttps://scigraph.springernature.com/ontologies/product-market-codes/H51000General Practice / Family Medicinehttps://scigraph.springernature.com/ontologies/product-market-codes/H24003Internal Medicinehttps://scigraph.springernature.com/ontologies/product-market-codes/H33002Pharmacotherapyhttps://scigraph.springernature.com/ontologies/product-market-codes/H69000Oncology  .Primary care (Medicine).General practice (Medicine).Internal medicine.Pharmacotherapy.Oncology.Primary Care Medicine.General Practice / Family Medicine.Internal Medicine.Pharmacotherapy.616.99449Alvarez Ricardo Hauthttp://id.loc.gov/vocabulary/relators/aut860186Cortés Javierauthttp://id.loc.gov/vocabulary/relators/autMattos-Arruda Leticiaauthttp://id.loc.gov/vocabulary/relators/autFalzon Maryauthttp://id.loc.gov/vocabulary/relators/autFasolo Angelicaauthttp://id.loc.gov/vocabulary/relators/autGandy Michaelauthttp://id.loc.gov/vocabulary/relators/autGianni Lucaauthttp://id.loc.gov/vocabulary/relators/autHarbeck Nadiaauthttp://id.loc.gov/vocabulary/relators/autPiccart Martineauthttp://id.loc.gov/vocabulary/relators/autZambelli Stefaniaauthttp://id.loc.gov/vocabulary/relators/autZardavas Dimitriosauthttp://id.loc.gov/vocabulary/relators/autBOOK9910438014903321Handbook of HER2-targeted agents in breast cancer1919318UNINA